{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.8","upperLimit":"60.9","value":"37.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"title":"Colorectal Cancer"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.0","upperLimit":"43.8","value":"16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"Gastroesophageal Cancer"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.6","upperLimit":"56.4","value":"38.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"title":"Non-Small Cell Lung Cancer"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.3","upperLimit":"57.3","value":"30.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"Ovarian Cancer"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"26.0","upperLimit":"68.9","value":"47.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"title":"Prostate Cancer"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.2","upperLimit":"77.8","value":"50.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"Squamous Cell Carcinoma of Head and Neck"}],"denoms":[{"counts":[{"groupId":"OG000","value":"103"}],"units":"Participants"}],"description":"Response using Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 criteria. CR was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 millimeter (mm) and normalization of tumor marker level of non-target lesions. PR was defined as at least a 30% decrease in sum of longest diameter of target lesions and for prostate cancer PR was defined as a ≥50% decrease in baseline prostate-specific antigen (PSA) value that was confirmed with a second value ≥3 weeks later. Progressive Disease (PD) was defined as at least 20% increase in sum of longest diameter of target lesions and minimum 5 mm increase over nadir. SD was defined as small changes that did not meet above criteria.","dispersionType":"90% Confidence Interval","groups":[{"description":"LY2523355: Dose determined by participant body surface area: 5 milligrams/square meter(mg/m²) or 6 mg/m², administered intravenously as a one hour infusion on Days 1, 2 and 3 of a 21 day cycle for up to 2 cycles (4 cycles for prostate cancer participants). Additional cycles administered based on participant response assessment.\n\nPegfilgrastim: 6 milligrams (mg), administered subcutaneously approximately 24 hours after third dose of LY2523355 on Day 4 of each 21-day cycle, for up to 2 cycles of LY2523355 administration (4 cycles for prostate cancer participants). Additional cycles of LY2523355 administered based on participant response assessment.","id":"OG000","title":"LY2523355"}],"paramType":"NUMBER","populationDescription":"All enrolled participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"Baseline until progressive disease up to 36 weeks post-baseline","title":"Percentage of Participants Who Achieved a Best Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}